Purpose: Hepatocellular carcinoma (HCC) is the largest subgroup of primary liver tumors. Ablative therapies, such as selective internal radiation therapy (SIRT), are used in late stages for patients with unresectable liver metastases and no response to other therapies. CCL2 (C-C motif chemokine ligand 2) is a potent monocyte chemoattractant. It is associated with tumor progression and metastasis. The role of circulating CCL2 as a biomarker in HCC undergoing selective internal radiation therapy remains unclear. Methods: A total of 41 patients (8 female, 33 male) suffering from HCC and undergoing SIRT were enrolled. Pre- and post-therapy changes in circulating CCL2 levels were determined by bead-based immunoassay and compared with clinical laboratory parameters and patient data. Results: A total of 32 patients exhibited survival beyond 60 days. It was observed that levels of CCL2 correlated with scores indicating a higher likelihood of non-survival and with the severity of the disease. Moreover, a significant inverse correlation was discovered between CCL2 levels and the survival of patients over 60 days in relation to counts of leukocytes, granulocytes, monocytes, and C-reactive protein. Conclusions: CCL2 may serve as a potential marker for patient survival after SIRT. The prediction of which HCC patients are likely to benefit from SIRT may be helpful in guiding therapeutic management.
目的：肝细胞癌（HCC）是原发性肝脏肿瘤中最大的亚型。对于无法切除肝转移且对其他疗法无反应的患者，晚期常采用消融疗法，如选择性内放射治疗（SIRT）。CCL2（C-C基序趋化因子配体2）是一种有效的单核细胞趋化因子，与肿瘤进展和转移相关。循环CCL2作为接受选择性内放射治疗的HCC患者生物标志物的作用尚不明确。方法：本研究共纳入41例（女性8例，男性33例）接受SIRT治疗的HCC患者。通过基于微珠的免疫分析法测定治疗前后循环CCL2水平的变化，并与临床实验室参数及患者数据进行比较。结果：共有32例患者生存期超过60天。研究发现，CCL2水平与提示较高非生存可能性的评分及疾病严重程度呈正相关。此外，CCL2水平与患者60天以上生存期在白细胞、粒细胞、单核细胞计数及C反应蛋白方面呈显著负相关。结论：CCL2可能作为SIRT术后患者生存期的潜在标志物。预测哪些HCC患者可能从SIRT中获益，有助于指导临床治疗决策。
肿瘤(癌症)患者之家